Digital PCR analysis of circulating nucleic acids

Clinical Biochemistry

Volumn 48, Issue 15, 2015, Pages 948-956

  Hudecova, Irena ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Digital PCR; Noninvasive cancer biomarker; Noninvasive prenatal diagnosis; Precision; Sensitivity; Transplantation medicine; Virology

Indexed keywords

CIRCULATING NUCLEIC ACID; MITOCHONDRIAL DNA; NUCLEIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA; RNA;

ANEUPLOIDY; BLOOD LEVEL; BREAST CANCER; CANCER RESEARCH; COLORECTAL CANCER; COPY NUMBER VARIATION; DIGITAL POLYMERASE CHAIN REACTION; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION ASSAY; GENE LOCUS; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; LUNG CANCER; NON INVASIVE PROCEDURE; NUCLEIC ACID ANALYSIS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PREGNANCY COMPLICATION; PRENATAL SCREENING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; VIROLOGY; ADVERSE EFFECTS; BLOOD; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; FEMALE; GENETIC SCREENING; MALE; METABOLISM; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PLASMA; PREGNANCY; PRENATAL DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRENDS;

BIOMARKERS; DIAGNOSIS, COMPUTER-ASSISTED; DNA; FEMALE; GENETIC TESTING; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; PRECISION MEDICINE; PREGNANCY; PRENATAL DIAGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 84943657622     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.03.015     Document Type: Review

References (120)

1. Mandel P., Metais P. Les acides nucléiques du plasma sanguin chezl'homme. C R Acad Sci Paris 1948, 142:241-243.
2. Lui Y.Y., Chik K.W., Chiu R.W., Ho C.Y., Lam C.W., Lo Y.M. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002, 48:421-427.
3. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001, 313:139-142.
4. Stroun M., Anker P., Maurice P., Lyautey J., Lederrey C., Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46:318-322.
5. Kopreski M.S., Benko F.A., Kwak L.W., Gocke C.D. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999, 5:1961-1965.
6. Lo Y.M., Corbetta N., Chamberlain P.F., Rai V., Sargent I.L., Redman C.W., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
7. Poon L.L., Leung T.N., Lau T.K., Lo Y.M. Presence of fetal RNA in maternal plasma. Clin Chem 2000, 46:1832-1834.
8. Lo Y.M., Tein M.S., Pang C.C., Yeung C.K., Tong K.L., Hjelm N.M. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 1998, 351:1329-1330.
9. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
10. Lun F.M., Chiu R.W., Chan K.C., Leung T.Y., Lau T.K., Lo Y.M. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem 2008, 54:1664-1672.
11. Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., Morley A.A. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992, 13:444-449.
12. Bhat S., Herrmann J., Armishaw P., Corbisier P., Emslie K.R. Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number. Anal Bioanal Chem 2009, 394:457-467.
13. Vogelstein B., Kinzler K.W. Digital PCR. Proc Natl Acad Sci U S A 1999, 96:9236-9241.
14. Zhou W., Galizia G., Lieto E., Goodman S.N., Romans K.E., Kinzler K.W., et al. Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 2001, 19:78-81.
15. Spurgeon S.L., Jones R.C., Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008, 3:e1662.
16. Morrison T., Hurley J., Garcia J., Yoder K., Katz A., Roberts D., et al. Nanoliter high throughput quantitative PCR. Nucleic Acids Res 2006, 34:e123.
17. Hindson B.J., Ness K.D., Masquelier D.A., Belgrader P., Heredia N.J., Makarewicz A.J., et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011, 83:8604-8610.
18. Pinheiro L.B., Coleman V.A., Hindson C.M., Herrmann J., Hindson B.J., Bhat S., et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 2012, 84:1003-1011.
19. Pekin D., Skhiri Y., Baret J.C., Le Corre D., Mazutis L., Salem C.B., et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011, 11:2156-2166.
20. Dressman D., Yan H., Traverso G., Kinzler K.W., Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 2003, 100:8817-8822.
21. Diehl F., Li M., He Y., Kinzler K.W., Vogelstein B., Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006, 3:551-559.
22. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102:16368-16373.
23. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
24. Diehl F., Schmidt K., Durkee K.H., Moore K.J., Goodman S.N., Shuber A.P., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008, 135:489-498.
25. Li M., Chen W.D., Papadopoulos N., Goodman S.N., Bjerregaard N.C., Laurberg S., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009, 27:858-863.
26. Taniguchi K., Uchida J., Nishino K., Kumagai T., Okuyama T., Okami J., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011, 17:7808-7815.
27. Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012, 18:3462-3469.
28. White R.A., Blainey P.C., Fan H.C., Quake S.R. Digital PCR provides sensitive and absolute calibration for high throughput sequencing. BMC Genomics 2009, 10:116.
29. Dingle T.C., Sedlak R.H., Cook L., Jerome K.R. Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. Clin Chem 2013, 59:1670-1672.
30. Sanders R., Huggett J.F., Bushell C.A., Cowen S., Scott D.J., Foy C.A. Evaluation of digital PCR for absolute DNA quantification. Anal Chem 2011, 83:6474-6484.
31. Sanders R., Mason D.J., Foy C.A., Huggett J.F. Evaluation of digital PCR for absolute RNA quantification. PLoS One 2013, 8:e75296.
32. Whale A.S., Cowen S., Foy C.A., Huggett J.F. Methods for applying accurate digital PCR analysis on low copy DNA samples. PLoS One 2013, 8:e58177.
33. Whale A.S., Huggett J.F., Cowen S., Speirs V., Shaw J., Ellison S., et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res 2012, 40:e82.
34. Hindson C.M., Chevillet J.R., Briggs H.A., Gallichotte E.N., Ruf I.K., Hindson B.J., et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013, 10:1003-1005.
35. Brunetto G.S., Massoud R., Leibovitch E.C., Caruso B., Johnson K., Ohayon J., et al. Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol 2014, 20:341-351.
36. Strain M.C., Lada S.M., Luong T., Rought S.E., Gianella S., Terry V.H., et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013, 8:e55943.
37. Sedlak R.H., Cook L., Cheng A., Magaret A., Jerome K.R. Clinical utility of droplet digital PCR for human cytomegalovirus. J Clin Microbiol 2014, 52:2844-2848.
38. Weisenberger D.J., Trinh B.N., Campan M., Sharma S., Long T.I., Ananthnarayan S., et al. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 2008, 36:4689-4698.
39. McDermott G.P., Do D., Litterst C.M., Maar D., Hindson C.M., Steenblock E.R., et al. Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR. Anal Chem 2013, 85:11619-11627.
40. Heyries K.A., Tropini C., Vaninsberghe M., Doolin C., Petriv O.I., Singhal A., et al. Megapixel digital PCR. Nat Methods 2011, 8:649-651.
41. Miotke L., Lau B.T., Rumma R.T., Ji H.P. High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR. Anal Chem 2014, 86:2618-2624.
42. Conrad D.F., Pinto D., Redon R., Feuk L., Gokcumen O., Zhang Y., et al. Origins and functional impact of copy number variation in the human genome. Nature 2010, 464:704-712.
43. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
44. Page K., Hava N., Ward B., Brown J., Guttery D.S., Ruangpratheep C., et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 2011, 104:1342-1348.
45. Petriv O.I., Heyries K.A., VanInsberghe M., Walker D., Hansen C.L. Methods for multiplex template sampling in digital PCR assays. PLoS One 2014, 9:e98341.
46. Gevensleben H., Garcia-Murillas I., Graeser M.K., Schiavon G., Osin P., Parton M., et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013, 19:3276-3284.
47. Jia W., Chen W., Kang J. The functions of microRNAs and long non-coding RNAs in embryonic and induced pluripotent stem cells. Genomics Proteomics Bioinformatics 2013, 11:275-283.
48. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
49. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54:482-490.
50. Wu L., Zhou H., Lin H., Qi J., Zhu C., Gao Z., et al. Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction 2012, 143:389-397.
51. Mouillet J.F., Chu T., Hubel C.A., Nelson D.M., Parks W.T., Sadovsky Y. The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta 2010, 31:781-784.
52. Ma J., Li N., Guarnera M., Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights 2013, 8:127-136.
53. Takahashi K., Yan I.K., Kim C., Kim J., Patel T. Analysis of extracellular RNA by digital PCR. Front Oncol 2014, 4:129.
54. Huggett J.F., Foy C.A., Benes V., Emslie K., Garson J.A., Haynes R., et al. The digital MIQE guidelines: minimum Information for publication of quantitative digital PCR experiments. Clin Chem 2013, 59:892-902.
55. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-174.
56. van Dijk M., Drewlo S., Oudejans C.B. Differential methylation of STOX1 in human placenta. Epigenetics 2010, 5:736-742.
57. Banister C.E., Koestler D.C., Maccani M.A., Padbury J.F., Houseman E.A., Marsit C.J. Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas. Epigenetics 2011, 6:920-927.
58. Evans M.I., Wright D.A., Pergament E., Cuckle H.S., Nicolaides K.H. Digital PCR for noninvasive detection of aneuploidy: power analysis equations for feasibility. Fetal Diagn Ther 2012, 31:244-247.
59. Lo Y.M., Lun F.M., Chan K.C., Tsui N.B., Chong K.C., Lau T.K., et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A 2007, 104:13116-13121.
60. Fan H.C., Quake S.R. Detection of aneuploidy with digital polymerase chain reaction. Anal Chem 2007, 79:7576-7579.
61. Tong Y.K., Jin S., Chiu R.W., Ding C., Chan K.C., Leung T.Y., et al. Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. Clin Chem 2010, 56:90-98.
62. Tong Y.K., Chiu R.W., Akolekar R., Leung T.Y., Lau T.K., Nicolaides K.H., et al. Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker. PLoS One 2010, 5:e15244.
63. Tsui N.B., Akolekar R., Chiu R.W., Chow K.C., Leung T.Y., Lau T.K., et al. Synergy of total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of trisomy 21. Clin Chem 2010, 56:73-81.
64. Lun F.M., Tsui N.B., Chan K.C., Leung T.Y., Lau T.K., Charoenkwan P., et al. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A 2008, 105:19920-19925.
65. Tsui N.B., Kadir R.A., Chan K.C., Chi C., Mellars G., Tuddenham E.G., et al. Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood 2011, 117:3684-3691.
66. Barrett A.N., McDonnell T.C., Chan K.C., Chitty L.S. Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia. Clin Chem 2012, 58:1026-1032.
67. Gu W., Koh W., Blumenfeld Y.J., El-Sayed Y.Y., Hudgins L., Hintz S.R., et al. Noninvasive prenatal diagnosis in a fetus at risk for methylmalonic acidemia. Genet Med 2014, 16:564-567.
68. Gardener G.J., Legler T.J., Hyett J.A., Liew Y.W., Flower R.L., Hyland C.A. Anti-D in pregnant women with the RHD(IVS3+1G>A)-associated DEL phenotype. Transfusion 2012, 52:2016-2019.
69. Tsui N.B., Hyland C.A., Gardener G.J., Danon D., Fisk N.M., Millard G., et al. Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3+1G>A) allele. Prenat Diagn 2013, 33:1214-1216.
70. Whitehead C.L., Tong S. Measuring hypoxia-induced RNA in maternal blood: a new way to identify critically hypoxic fetuses in utero?. Expert Rev Mol Diagn 2014, 14:509-511.
71. Whitehead C., Teh W.T., Walker S.P., Leung C., Mendis S., Larmour L., et al. Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in utero fetal hypoxic status. BMC Med 2013, 11:256.
72. Campbell P.J., Pleasance E.D., Stephens P.J., Dicks E., Rance R., Goodhead I., et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 2008, 105:13081-13086.
73. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
74. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
75. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
76. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013, 10:472-484.
77. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24.
78. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
79. Sozzi G., Conte D., Mariani L., Lo Vullo S., Roz L., Lombardo C., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
80. Jung K., Stephan C., Lewandowski M., Klotzek S., Jung M., Kristiansen G., et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004, 205:173-180.
81. Huang Z.H., Li L.H., Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006, 243:64-70.
82. Ellinger J., Bastian P.J., Ellinger N., Kahl P., Perabo F.G., Buttner R., et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett 2008, 264:274-280.
83. Ellinger J., Wittkamp V., Albers P., Perabo F.G., Mueller S.C., von Ruecker A., et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 2009, 181:363-371.
84. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
85. Jelovac D., Beaver J.A., Balukrishna S., Wong H.Y., Toro P.V., Cimino-Mathews A., et al. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Hum Pathol 2014, 45:880-883.
86. Beaver J.A., Jelovac D., Balukrishna S., Cochran R.L., Croessmann S., Zabransky D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014, 20:2643-2650.
87. Dawson S.J., Rosenfeld N., Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 369:93-94.
88. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
89. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
90. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
91. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
92. Yung T.K., Chan K.C., Mok T.S., Tong J., To K.F., Lo Y.M. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009, 15:2076-2084.
93. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014, 20:1698-1705.
94. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
95. Kopreski M.S., Benko F.A., Kwee C., Leitzel K.E., Eskander E., Lipton A., et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997, 76:1293-1299.
96. de Kok J.B., van Solinge W.W., Ruers T.J., Roelofs R.W., van Muijen G.N., Willems J.L., et al. Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 1997, 57:601-604.
97. Anker P., Lefort F., Vasioukhin V., Lyautey J., Lederrey C., Chen X.Q., et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997, 112:1114-1120.
98. Gocke C.D., Benko F.A., Kopreski M.S., McGarrity T.J. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas. Ann N Y Acad Sci 2000, 906:44-50.
99. Taly V., Pekin D., Benhaim L., Kotsopoulos S.K., Le Corre D., Li X., et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013, 59:1722-1731.
100. Taylor R.W., Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005, 6:389-402.
101. Zhong S., Ng M.C., Lo Y.M., Chan J.C., Johnson P.J. Presence of mitochondrial tRNA(Leu(UUR)) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus. J Clin Pathol 2000, 53:466-469.
102. Chiu R.W., Chan L.Y., Lam N.Y., Tsui N.B., Ng E.K., Rainer T.H., et al. Quantitative analysis of circulating mitochondrial DNA in plasma. Clin Chem 2003, 49:719-726.
103. Mehra N., Penning M., Maas J., van Daal N., Giles R.H., Voest E.E. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 2007, 13:421-426.
104. Zachariah R.R., Schmid S., Buerki N., Radpour R., Holzgreve W., Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 2008, 112:843-850.
105. Ellinger J., Albers P., Muller S.C., von Ruecker A., Bastian P.J. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int 2009, 104:48-52.
106. Ellinger J., Muller D.C., Muller S.C., Hauser S., Heukamp L.C., von Ruecker A., et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol 2012, 30:509-515.
107. Kohler C., Radpour R., Barekati Z., Asadollahi R., Bitzer J., Wight E., et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009, 8:105.
108. Podlesniy P., Figueiro-Silva J., Llado A., Antonell A., Sanchez-Valle R., Alcolea D., et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 2013, 74:655-668.
109. Lui Y.Y., Woo K.S., Wang A.Y., Yeung C.K., Li P.K., Chau E., et al. Origin of plasma cell-free DNA after solid organ transplantation. Clin Chem 2003, 49:495-496.
110. Snyder T.M., Khush K.K., Valantine H.A., Quake S.R. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 2011, 108:6229-6234.
111. Garcia Moreira V., Prieto Garcia B., Baltar Martin J.M., Ortega Suarez F., Alvarez F.V. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clin Chem 2009, 55:1958-1966.
112. Gadi V.K., Nelson J.L., Boespflug N.D., Guthrie K.A., Kuhr C.S. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. Clin Chem 2006, 52:379-382.
113. Beck J., Bierau S., Balzer S., Andag R., Kanzow P., Schmitz J., et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 2013, 59:1732-1741.
114. Oellerich M., Schutz E., Kanzow P., Schmitz J., Beck J., Kollmar O., et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 2014, 36:136-140.
115. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191.
116. White R.A., Quake S.R., Curr K. Digital PCR provides absolute quantitation of viral load for an occult RNA virus. J Virol Methods 2012, 179:45-50.
117. Hayden R.T., Gu Z., Ingersoll J., Abdul-Ali D., Shi L., Pounds S., et al. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol 2013, 51:540-546.
118. Huggett J.F., Cowen S., Foy C.A. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem 2015, 61:79-88.
119. Fan H.C., Blumenfeld Y.J., El-Sayed Y.Y., Chueh J., Quake S.R. Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy. Am J Obstet Gynecol 2009, 200(543):e1-e7.
120. Kiselinova M., Pasternak A.O., De Spiegelaere W., Vogelaers D., Berkhout B., Vandekerckhove L. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS One 2014, 9:e85999.